Varicella vaccine given subcutaneously (under the skin). It is recommended for all children under 13 and for everyone 13 or older who has never had chickenpox. In the United States two doses are recommended. In the first case a first dose is administered at 12 to 15 months and a second dose at age 4–6 years. For people older than 13 the two doses are administered 4 to 8 weeks apart. The varicella vaccine did not become widely available in the United States until 1995. In the UK, the vaccine is only recommended in people who are particularly vulnerable to chickenpox. The
Huntington's disease may be beneficial as it translates into long term maintenance of motor and functional performance. Rehabilitation during the late stage aims to compensate for motor and functional losses. For long-term independent management, the therapist may develop home exercise programs for appropriate people. Additionally, an increasing number of people with Huntington's disease are turning to palliative care, which aims to improve quality of life through the treatment of the symptoms and stress of serious illness, in addition to their other treatments. Tetrabenazine was approved in 2000 for treatment of chorea in Huntington's disease in the EU, and in 2008 in the